Case Study Discussion: Long-Term Management of Sickle Cell Anemia in Pediatric Patients Diagnosed via Newborn Screening

Healthcare professionals preparing to care for children with sickle cell anemia benefit from understanding evidence-based, age-specific management strategies that address preventive care, complication risks, and coordinated support across developmental stages.

A 2-month-old is identified during newborn screening with sickle cell anemia. Prompt confirmation and early preventive interventions significantly reduce morbidity and mortality risks associated with this condition.

Discussion Questions

• How would you manage this patient at 2 months, 2 years, 6 years, and at 13 years old? Current evidence-based guidelines recommend starting prophylactic penicillin, immunizations, and considering hydroxyurea early to modify disease severity.
• What are the issues for each stage in development? Complications such as pain crises, infections, stroke risk, and growth delays often vary by age and require vigilant monitoring.
• Where would you refer this child? Comprehensive sickle cell centers or pediatric hematologists provide specialized expertise essential for optimal outcomes.
• How would you coordinate the care of this child? Effective coordination involves a multidisciplinary team including primary care providers, specialists, and family support services to ensure continuity and holistic management.

Submission Instructions

Your initial post should be at least 500 words, formatted and cited in current APA style with support from at least 2 academic sources.

Example Student Response (Illustrative Sample)

Upon newborn screening confirmation of sickle cell anemia in a 2-month-old infant, immediate management includes daily prophylactic penicillin to prevent pneumococcal infections, completion of the primary vaccination series with additional pneumococcal and meningococcal vaccines, and parental education on fever recognition and prompt medical attention. Hydroxyurea therapy is now recommended as early as 9 months for most children to reduce vaso-occlusive events and acute chest syndrome. At 2 years, transcranial Doppler ultrasonography screening begins annually to assess stroke risk, with chronic transfusion therapy initiated if velocities are elevated.

By age 6, school-related challenges emerge, including pain episodes that may affect attendance and cognitive impacts from silent infarcts, necessitating individualized education plans and pain management strategies. At 13 years, adolescence brings concerns about puberty delays, increased pain frequency, and preparation for transition to adult care, including discussions on reproductive health and emerging curative options such as gene therapy.

Referral to a comprehensive pediatric sickle cell program or hematologist is critical from diagnosis onward. Care coordination involves regular follow-up with a multidisciplinary team that includes hematology, primary care, psychology, and social work to address medical, educational, and psychosocial needs. According to recent American Academy of Pediatrics guidance, routine health supervision with targeted screenings and family-centered education improves long-term outcomes for children with sickle cell anemia (Power-Hays et al., 2024, https://doi.org/10.1542/peds.2024-066423).

Learning Materials and Recommended References

The following peer-reviewed sources (published 2018–2026) provide current, evidence-based guidance on pediatric sickle cell disease management:

• Power-Hays, A., Patterson, A., Trailsmith, M., Dussel, V., Glader, B., Craddock, M., Lee, M., McCauley, K., Nuehring, N., Sobota, A., Steadman, J. and Wells, L. (2024) ‘Health supervision for children and adolescents with sickle cell anemia: clinical report’, Pediatrics, 154(2), e2024066423. Available at: https://doi.org/10.1542/peds.2024-066423.
• Meier, E.R., Ramakrishnan, A. and Fasano, R.M. (2023) ‘The evolving treatment landscape for children with sickle cell disease’, The Lancet Child & Adolescent Health, 7(12), pp. 889–900. Available at: https://doi.org/10.1016/S2352-4642(23)00201-8.
• Brandow, A.M., Carroll, C.P., Creary, S., Edwards-Elliott, R., Glass, P., Jasti, J., Kamel, O., Myers, K., Nelson, S.C., Sadak, K.T., Schaefer, S., Shenoy, S., Singh, S., Stinson, J., Suarez, M., Yusuf, F. and Darby, J. (2020) ‘American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain’, Blood Advances, 4(12), pp. 2656–2701. Available at: https://doi.org/10.1182/bloodadvances.2020001851.
• DeBaun, M.R., Jordan, L.C., King, A.A., Schatz, J., Vichinsky, E., Fox, C.K., McKinstry, R.C., Telfer, P., Rodeghier, M., Roberts, D.O., Files, B., Kawadler, J., Kirkham, F.J., Murad, M.H., Noonan, P.M., Piccone, C.M., Quinn, C.T., Roberts, D.O., Rogers, Z.R., Smith-Whitley, K., Strouse, J.J., Kwiatkowski, J.L., Wilfong, A.A., Williams, B.W., Woods, G.M. and Casella, J.F. (2020) ‘American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults’, Blood Advances, 4(8), pp. 1554–1588. Available at: https://doi.org/10.1182/bloodadvances.2019001142.